S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The Day of Financial Reckoning Is Near (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
3rd Massive Dollar Upheaval Has Started (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The Day of Financial Reckoning Is Near (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
3rd Massive Dollar Upheaval Has Started (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The Day of Financial Reckoning Is Near (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
3rd Massive Dollar Upheaval Has Started (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The Day of Financial Reckoning Is Near (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
3rd Massive Dollar Upheaval Has Started (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
NASDAQ:NVAX

Novavax - NVAX Stock Forecast, Price & News

$42.88
+0.58 (+1.37%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$41.38
$44.02
50-Day Range
$36.28
$76.12
52-Week Range
$34.88
$277.80
Volume
4.89 million shs
Average Volume
6.16 million shs
Market Capitalization
$3.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$151.00

Novavax MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
252.1% Upside
$151.00 Price Target
Short Interest
Healthy
20.90% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
-0.09mentions of Novavax in the last 14 days
Based on 27 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-48.19%
From $20.98 to $10.87 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

363rd out of 1,124 stocks

Biological Products, Except Diagnostic Industry

58th out of 176 stocks

NVAX stock logo

About Novavax (NASDAQ:NVAX) Stock

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Analyst Upgrades and Downgrades

NVAX has been the subject of several analyst reports. Bank of America began coverage on Novavax in a research note on Friday, May 20th. They issued an "underperform" rating and a $35.00 target price for the company. B. Riley reduced their price target on shares of Novavax from $181.00 to $171.00 in a research report on Friday, July 22nd. Cowen dropped their price objective on shares of Novavax to $110.00 in a research report on Monday. Cantor Fitzgerald lifted their target price on shares of Novavax from $146.00 to $168.00 in a report on Wednesday, June 8th. Finally, Cowen lowered their price target on Novavax from $150.00 to $110.00 and set an "outperform" rating for the company in a report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Novavax presently has a consensus rating of "Hold" and an average target price of $151.00.

Novavax Stock Performance

Shares of NVAX Stock traded up $0.58 during mid-day trading on Tuesday, reaching $42.88. 4,885,391 shares of the company were exchanged, compared to its average volume of 6,156,194. The business's 50 day simple moving average is $52.67 and its 200 day simple moving average is $62.20. The company has a market capitalization of $3.35 billion, a P/E ratio of -2.20, a P/E/G ratio of 0.05 and a beta of 1.52. Novavax has a fifty-two week low of $34.88 and a fifty-two week high of $277.80.

Novavax (NASDAQ:NVAX - Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing the consensus estimate of $5.51 by ($12.04). The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $1.02 billion. Novavax had a negative return on equity of 572.54% and a negative net margin of 114.32%. Novavax's revenue was down 37.6% on a year-over-year basis. During the same period in the prior year, the business earned ($4.75) earnings per share. On average, analysts forecast that Novavax will post 20.98 EPS for the current year.

Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Stock News Headlines

Is it Time to Cash Out Novavax Stock?
Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S.
Why Novavax Stock Eked Out a Gain Today
1 Reason to Sell Novavax Stock, and 1 Reason to Buy
Novavax (NASDAQ:NVAX) Given New $110.00 Price Target at Cowen
Novavax (NASDAQ:NVAX) Shares Gap Down After Earnings Miss
See More Headlines
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Company Calendar

Last Earnings
8/08/2022
Today
8/17/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,541
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$151.00
High Stock Price Forecast
$209.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+252.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-1,743,750,000.00
Net Margins
-114.32%
Pretax Margin
-112.25%

Debt

Sales & Book Value

Annual Sales
$1.15 billion
Book Value
($4.65) per share

Miscellaneous

Free Float
76,494,000
Market Cap
$3.35 billion
Optionable
Optionable
Beta
1.52

Social Links


Key Executives

  • Mr. Stanley Charles Erck (Age 74)
    Pres, CEO & Director
    Comp: $1.12M
  • Mr. James Patrick Kelly C.F.A. (Age 56)
    Exec. VP, CFO & Treasurer
    Comp: $355.23k
  • Mr. John A. Herrmann III (Age 56)
    Exec. VP, Chief Legal Officer & Corp. Sec.
    Comp: $657.8k
  • Mr. John Joseph Trizzino B.S. (Age 62)
    M.B.A., Exec. VP and Chief Bus. & Commercial Officer
    Comp: $636.85k
  • Dr. Gregory M. Glenn (Age 68)
    Pres of R&D
    Comp: $813.44k
  • Mr. Richard P. Crowley (Age 65)
    Exec. VP & COO
  • Dr. Gale E. Smith (Age 72)
    Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist
  • Mr. Biegie Lee
    Sr. VP & Chief Information Officer
  • Ms. Silvia Taylor M.B.A.
    MBA, Sr. VP of Global Corp. Affairs & Investor Relations
  • Mr. Troy Morgan Esq. (Age 51)
    J.D., Sr. VP & Chief Compliance Officer













NVAX Stock - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVAX shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price forecast for 2022?

8 Wall Street research analysts have issued 12-month target prices for Novavax's shares. Their NVAX share price forecasts range from $35.00 to $209.00. On average, they expect the company's share price to reach $151.00 in the next twelve months. This suggests a possible upside of 252.1% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How have NVAX shares performed in 2022?

Novavax's stock was trading at $143.07 on January 1st, 2022. Since then, NVAX stock has decreased by 70.0% and is now trading at $42.88.
View the best growth stocks for 2022 here
.

When is Novavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NVAX earnings forecast
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Monday, August, 8th. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing the consensus estimate of $5.51 by $12.04. The biopharmaceutical company earned $186 million during the quarter, compared to analysts' expectations of $1.02 billion. Novavax had a negative trailing twelve-month return on equity of 572.54% and a negative net margin of 114.32%. The company's revenue for the quarter was down 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($4.75) EPS.

When did Novavax's stock split?

Shares of Novavax reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax issued an update on its FY 2022 earnings guidance on Tuesday, August, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.00 billion-$2.30 billion, compared to the consensus revenue estimate of $4.27 billion.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (3.80%), Citadel Advisors LLC (0.00%), Jane Street Group LLC (0.00%), JPMorgan Chase & Co. (0.00%), Group One Trading L.P. (0.00%) and Northern Trust Corp (0.45%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends
.

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $42.88.

How much money does Novavax make?

Novavax (NASDAQ:NVAX) has a market capitalization of $3.35 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($19.46) on an earnings per share basis.

How many employees does Novavax have?

The company employs 1,541 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.

This page (NASDAQ:NVAX) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.